Latest / DDReg Knowledge Capsule / Winning AIFA Drug Reimbursement in Italy: Regulatory & HTA Roadmap

Transcript

Winning AIFA Drug Reimbursement in Italy: Regulatory & HTA Roadmap · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to the D.D. Reg Knowledge Capsule. Imagine spending 10
• 0:04
  Speaker 1: years and over a billion dollars developing a life-saving therapy.
• 0:08
  Speaker 2: Yeah, that is not an exaggeration either.
• 0:10
  Speaker 1: Right. It takes massive resources. You navigate the clinical trials,
• 0:13
  Speaker 1: secure your European regulatory approval, and, you know, the team
• 0:16
  Speaker 1: pops the champagne.
• 0:17
  Speaker 2: As they should.
• 0:18
  Speaker 1: I mean, it's a huge scientific milestone.
• 0:20
  Speaker 2: Exactly.
• 0:21
  Speaker 1: But then, months later, you discover that a doctor in
• 0:24
  Speaker 1: Milan still legally cannot prescribe your drug to a patient
• 0:27
  Speaker 1: who desperately needs it.
• 0:29
  Speaker 2: Which is just a massive reality check for a lot
• 0:31
  Speaker 2: of companies.
• 0:32
  Speaker 1: It really is. So today we are looking at the
• 0:34
  Speaker 1: harsh reality of the Italian pharmaceutical market, and we're relying
• 0:38
  Speaker 1: on a really comprehensive regulatory guide from DD Reg Pharma.
• 0:42
  Speaker 1: We're focusing on the Italian Medicines Agency, or IFA, and
• 0:46
  Speaker 1: the Health Technology Assessment, the HTA processes. Right.
• 0:49
  Speaker 2: The HTA is really the crux of the issue here. Okay.
• 0:53
  Speaker 1: Let's unpack this, because bringing a drug to market in
• 0:55
  Speaker 1: Italy isn't a single regulatory hurdle. It is Honestly, an intricate,
• 1:01
  Speaker 1: multilayered obstacle course where clinical science and national economics just
• 1:06
  Speaker 1: completely collide. Yeah.
• 1:07
  Speaker 2: And the friction you were describing right at the start,
• 1:11
  Speaker 2: it's the most dangerous blind spot for any pharmaceutical executive.
• 1:15
  Speaker 1: How so?
• 1:15
  Speaker 2: Well, the ultimate goal of drug development isn't to just
• 1:18
  Speaker 2: acquire a regulatory certificate with a stamp on it. A
• 1:21
  Speaker 2: piece of paper does not heal anyone.
• 1:23
  Speaker 1: Right. It doesn't actually treat the patient.
• 1:25
  Speaker 2: Exactly. The actual mission is patient access. getting that medicine
• 1:30
  Speaker 2: into the hands of the people who need it. And
• 1:32
  Speaker 2: to accomplish that in Italy, you have to completely dismantle
• 1:35
  Speaker 2: the assumption that regulatory strategy and commercial access are like
• 1:39
  Speaker 2: sequential steps.
• 1:41
  Speaker 1: Meaning you can't just do one and then figure out
• 1:44
  Speaker 1: the other later.
• 1:45
  Speaker 2: Right. If you are not seamlessly aligning your regulatory submissions,
• 1:49
  Speaker 2: your clinical evidence generation, and your economic arguments from the
• 1:52
  Speaker 2: very beginning of the product lifecycle, you are already years behind.
• 1:56
  Speaker 1: That distinction is exactly where we need to start. Reading
• 1:59
  Speaker 1: through the DD-REG materials, it becomes incredibly clear that there
• 2:03
  Speaker 1: is a fatal misconception in how companies approach market entry.
• 2:06
  Speaker 2: Oh, absolutely. The finish line illusion?
• 2:09
  Speaker 1: Yes.
• 2:10
  Speaker 2: There is this persistent idea that marketing authorization, the legal
• 2:14
  Speaker 2: right to sell the drug, is the finish line. But
• 2:17
  Speaker 2: the sources explicitly separate marketing authorization from IEFA's pricing and
• 2:21
  Speaker 2: reimbursement decisions.
• 2:23
  Speaker 1: They are entirely different beasts.
• 2:25
  Speaker 2: They are entirely different beasts.
• 2:27
  Speaker 1: Right. And I like to think of it like getting
• 2:29
  Speaker 1: a driver's license. The license, the marketing authorization, proves you
• 2:33
  Speaker 1: can legally drive. But it doesn't automatically give you a
• 2:36
  Speaker 1: car or, you know, pay for your gas. That's the
• 2:39
  Speaker 1: reimbursement part.
• 2:40
  Speaker 2: That's a really great way to frame it.
• 2:42
  Speaker 1: But I do want to push back on this separation, though,
• 2:44
  Speaker 1: because if you are a drug developer, it can feel redundant.
• 2:48
  Speaker 1: I mean, if the European Medicines Agency, the EMA, already
• 2:51
  Speaker 1: scrutinized your clinical trial data... verified your manufacturing quality, and
• 2:55
  Speaker 1: agreed the drug is safe and effective, why wouldn't they
• 2:57
  Speaker 1: automatically fund it? Why does IEFA essentially force you to
• 3:01
  Speaker 1: re-litigate the science just to talk about price?
• 3:04
  Speaker 2: If we connect this to the bigger picture, it comes
• 3:06
  Speaker 2: down to the fundamental difference between absolute efficacy and relative value.
• 3:11
  Speaker 1: Okay, break that down for me.
• 3:13
  Speaker 2: So, the EMA's marketing authorization process operates in, well, kind
• 3:18
  Speaker 2: of a scientific vacuum. They are asking one main thing.
• 3:21
  Speaker 2: Does this molecule... do what the manufacturer claims it does safely.
• 3:26
  Speaker 1: Right. So that's an absolute metric.
• 3:28
  Speaker 2: Exactly.
• 3:28
  Speaker 1: It works or it doesn't.
• 3:29
  Speaker 2: Exactly. But IFA's pricing and reimbursement process, the P &
• 3:33
  Speaker 2: R process, that operates in the real world of national
• 3:37
  Speaker 2: health care economics. They are evaluating relative value.
• 3:41
  Speaker 1: Because they have a limited budget. Right.
• 3:44
  Speaker 2: The Italian national health care system has to figure out
• 3:46
  Speaker 2: if your drug offers a significant enough improvement over the
• 3:50
  Speaker 2: current standard of care that to justify reallocating public funds.
• 3:54
  Speaker 1: So it's the difference between proving the drug works and
• 3:57
  Speaker 1: proving the drug works better than, say, the five cheaper
• 3:59
  Speaker 1: alternatives already sitting on the pharmacy shelf.
• 4:01
  Speaker 2: Precisely.
• 4:02
  Speaker 1: You have to prove it's worth the extra money. Which
• 4:04
  Speaker 1: means before you can even begin that intense economic negotiation,
• 4:08
  Speaker 1: you need your baseline marketing authorization. And the DD Reg
• 4:11
  Speaker 1: Guide outlines four distinct regulatory entry points or, you know,
• 4:15
  Speaker 1: doors to the Italian market.
• 4:16
  Speaker 2: Right. The four main pathways. Yeah.
• 4:18
  Speaker 1: So you've got the centralized procedure, the national procedure, the
• 4:21
  Speaker 1: decentralized procedure, and the mutual recognition procedure. I want to
• 4:25
  Speaker 1: look at the strategic mechanics here. If the centralized procedure
• 4:29
  Speaker 1: grants you a single marketing authorization valid across the entire
• 4:33
  Speaker 1: European Union simultaneously, why would a company ever waste time
• 4:37
  Speaker 1: bothering with the national or mutual recognition pathways?
• 4:40
  Speaker 2: It seems counterintuitive, right? Yeah.
• 4:42
  Speaker 1: I mean, why not just use the master key to
• 4:43
  Speaker 1: open the whole continent at once?
• 4:45
  Speaker 2: Well, it is a matter of eligibility first and market
• 4:48
  Speaker 2: strategy second. The centralized procedure isn't an option for everyone.
• 4:53
  Speaker 2: It is mandatory for specific categories.
• 4:56
  Speaker 1: Like what kind of categories?
• 4:57
  Speaker 2: Like biologics, advanced therapy medicinal products, or new active substances
• 5:02
  Speaker 2: that are treating cancer, HIV, or diabetes. If your drug
• 5:06
  Speaker 2: falls into those buckets, you have to use the central
• 5:09
  Speaker 2: EMA pathway.
• 5:10
  Speaker 1: Okay, so you don't even have a choice there. But
• 5:12
  Speaker 1: what if it doesn't fall into those buckets?
• 5:14
  Speaker 2: That is where the strategic calculus shifts entirely. A company
• 5:18
  Speaker 2: might actively avoid the centralized route because they want to
• 5:22
  Speaker 2: control their reference pricing.
• 5:23
  Speaker 1: Oh, meaning they don't want a lower price negotiated in
• 5:26
  Speaker 1: one country to drag down the price in another. Precisely.
• 5:30
  Speaker 2: The underlying mechanism. Let's say a company uses the decentralized procedure,
• 5:34
  Speaker 2: the DCP.
• 5:35
  Speaker 1: Right, the DCP. How does that work?
• 5:37
  Speaker 2: This is used when a drug isn't authorized anywhere in
• 5:39
  Speaker 2: the EU yet, but the company wants to target several
• 5:42
  Speaker 2: specific member states simultaneously. They might choose to enter markets
• 5:46
  Speaker 2: where they know their clinical data aligns perfectly with local
• 5:49
  Speaker 2: HTA requirements.
• 5:50
  Speaker 1: Ah, to establish a really strong initial price.
• 5:54
  Speaker 2: Exactly. Or, alternatively, they might use the mutual recognition procedure,
• 5:58
  Speaker 2: the MRP. This is where you secure authorization in one
• 6:01
  Speaker 2: specific member state first.
• 6:03
  Speaker 1: So you pick a country that really likes your data.
• 6:06
  Speaker 2: Right, perhaps a market with a highly favorable view of
• 6:09
  Speaker 2: your specific therapeutic area. And once that is locked in...
• 6:12
  Speaker 2: you ask Italy to recognize and adopt that existing approval.
• 6:16
  Speaker 1: Oh, wow. So it's a very tailored approach.
• 6:18
  Speaker 2: It is. It allows a smaller company to stagger their launch,
• 6:21
  Speaker 2: generate early revenue, and carefully manage the narrative of their
• 6:25
  Speaker 2: drug's value state by state, rather than risking a uniform,
• 6:29
  Speaker 2: continent-wide assessment that might not account for regional nuances.
• 6:33
  Speaker 1: That changes the entire perspective.
• 6:36
  Speaker 2: It's not just about getting approval. It's about choreographing your
• 6:38
  Speaker 2: market entry to protect your drug's perceived value.
• 6:42
  Speaker 1: Which is critical once you get to Italy. Yeah.
• 6:44
  Speaker 2: Because once you secure that authorization through whichever door you choose,
• 6:48
  Speaker 2: you step into AIFA's evaluation gauntlet. And here's where it
• 6:52
  Speaker 2: gets really interesting. Because AIFA's criteria for determining what your
• 6:56
  Speaker 2: drug is actually worth financially are unforgiving.
• 7:00
  Speaker 1: Oh, they are incredibly strict.
• 7:02
  Speaker 2: The sources detail specific evaluation criteria. They are looking at
• 7:06
  Speaker 2: the severity of the therapeutic need, the added therapeutic benefit,
• 7:10
  Speaker 2: the quality of your clinical evidence, the economic and budget impact,
• 7:14
  Speaker 2: and exactly where this drug fits into the current place
• 7:17
  Speaker 2: in therapy.
• 7:18
  Speaker 1: It's a massive burden of proof.
• 7:21
  Speaker 2: It is. This isn't just about showing up with a
• 7:23
  Speaker 2: functioning product. I look at this like pitching on Shark Tank.
• 7:27
  Speaker 1: Oh, I like that comparison. Right?
• 7:28
  Speaker 2: Because having a working prototype, the approved drug, just isn't enough.
• 7:32
  Speaker 2: You have to prove the market need and the unit
• 7:35
  Speaker 2: economics to get an investment, which is the reimbursement. You
• 7:39
  Speaker 2: can't just walk in with a cool gadget. What's fascinating
• 7:41
  Speaker 2: here is how deeply IFAS scrutinizes that claim, particularly when
• 7:44
  Speaker 2: a company claims their drug has quote-unquote innovative status.
• 7:48
  Speaker 1: Yeah, because everyone wants to be called innovative, right? Of course.
• 7:52
  Speaker 2: But the DD Reg Guide specifically warns against assuming that
• 7:55
  Speaker 2: a novel biological mechanism or some cool new drug delivery
• 7:59
  Speaker 2: technology automatically equals innovation in the eyes of the regulator.
• 8:03
  Speaker 1: So just being new science isn't enough?
• 8:05
  Speaker 2: Not at all. IFA demands strict, undeniable proof of unmet
• 8:09
  Speaker 2: therapeutic need combined with substantial added therapeutic benefit.
• 8:14
  Speaker 1: Meaning comparative clinical value is king.
• 8:16
  Speaker 2: Yes. Your clinical narrative must seamlessly match your economic argument.
• 8:21
  Speaker 2: If your clinical trials were designed to show, say, just
• 8:24
  Speaker 2: non-inferiority to a placebo, but IFA's HTA requires you to
• 8:29
  Speaker 2: show superiority to the current leading treatment, your dossier is
• 8:32
  Speaker 2: going to fail the value test, no matter how novel
• 8:34
  Speaker 2: the science is. Wow.
• 8:36
  Speaker 1: And the friction doesn't even stop at the national level.
• 8:39
  Speaker 1: The sources highlight this vital detail, a massive operational hurdle.
• 8:43
  Speaker 1: Italy's health care system relies heavily on regional autonomy.
• 8:47
  Speaker 2: The regional fragmentation is notoriously difficult.
• 8:50
  Speaker 1: Yeah, national approver from AIFA does not guarantee smooth regional implementation.
• 8:55
  Speaker 1: You can win the grueling national negotiation, get your pricing
• 8:59
  Speaker 1: agreed upon in Rome, but the local formularies and regional
• 9:02
  Speaker 1: procurement boards dictate whether a hospital in Naples or Milan
• 9:07
  Speaker 1: can actually buy it.
• 9:08
  Speaker 2: And that is exactly where launch timelines often fall apart.
• 9:11
  Speaker 2: Pharmaceutical companies have to maintain persistent, localized market access strategies
• 9:16
  Speaker 2: long after the national ink is dry.
• 9:18
  Speaker 1: So the job isn't done after AIFA says yes.
• 9:20
  Speaker 2: Not even close. The evidence you use to convince the
• 9:23
  Speaker 2: national HTA might need to be completely repackaged to address
• 9:26
  Speaker 2: the specific budgetary constraints or patient demographics of a single
• 9:30
  Speaker 2: Italian region.
• 9:31
  Speaker 1: So you are basically fighting a two-front war. And to
• 9:35
  Speaker 1: make this environment even more volatile, IEFA completely rewrote the
• 9:38
  Speaker 1: rulebook recently.
• 9:39
  Speaker 2: Yes, they did. Massive overhaul.
• 9:42
  Speaker 1: The DD-REG material details several 2026 legislative curveballs. For instance,
• 9:47
  Speaker 1: in April 2026, IEFA implemented Resolution No.
• 9:50
  Speaker 2: 88-2025. Right, which introduced entirely updated HTA dossier guidelines.
• 9:56
  Speaker 1: And the sources are incredibly explicit about this, warning against usurpation.
• 10:00
  Speaker 1: using older dossier templates. The framework for how clinical and
• 10:03
  Speaker 1: economic evidence is structured has fundamentally shifted.
• 10:06
  Speaker 2: The lying on historical successes is a guaranteed point of
• 10:09
  Speaker 2: failure under the April 2026 guidelines.
• 10:11
  Speaker 1: So you can't just copy-paste your last successful application?
• 10:15
  Speaker 2: Definitely not. AIFA has changed the architecture of the data
• 10:18
  Speaker 2: they require. If a company tries to retrofit their current
• 10:21
  Speaker 2: clinical data into an old submission template, the regulators will
• 10:25
  Speaker 2: simply reject it.
• 10:25
  Speaker 1: Just flat out reject it?
• 10:26
  Speaker 2: Yes, because the required data fields, particularly those correlating clinical
• 10:30
  Speaker 2: outcomes directly with economic impact, will be either empty or misaligned.
• 10:35
  Speaker 2: And that structural change was compounded just a few months later.
• 10:39
  Speaker 1: Right, with the September 2026 updates to the e-dossier. This
• 10:43
  Speaker 1: addresses the requirements for the EU Joint Clinical Assessment that JCA,
• 10:46
  Speaker 1: under Regulation 2021-2022, 2282. This sounds like an absolute labyrinth.
• 10:51
  Speaker 2: It is incredibly complex.
• 10:53
  Speaker 1: Applicants now have to navigate specific JCA fields within their
• 10:56
  Speaker 1: Italian submissions, right? So they are blending European level health
• 11:01
  Speaker 1: technology assessments with Italy's specific national requirements.
• 11:05
  Speaker 2: The JCA integration is a massive paradigm shift. Historically, a
• 11:09
  Speaker 2: company might have relied on entirely separate narratives for the
• 11:12
  Speaker 2: European regulators and the Italian HTA.
• 11:15
  Speaker 1: Like two different stories for two different audiences.
• 11:17
  Speaker 2: Exactly. But the September 2026 eDossier updates essentially force companies
• 11:22
  Speaker 2: to bridge that gap in a single system. You have
• 11:25
  Speaker 2: to input European-level clinical assessments, but contextualize them perfectly for
• 11:29
  Speaker 2: the Italian standard of care.
• 11:31
  Speaker 1: That sounds really risky if the standards don't match up.
• 11:34
  Speaker 2: It is. If the EU assessment compares your drug to
• 11:37
  Speaker 2: a therapy that isn't widely used in Italy, you have
• 11:40
  Speaker 2: to proactively address that discrepancy in your eDossier. Otherwise, AFIA
• 11:44
  Speaker 2: will flag the submission as clinically irrelevant to their specific population.
• 11:49
  Speaker 1: I want to look at how companies actually navigate these
• 11:52
  Speaker 1: submissions practically, because the sources mention AFIA has distinct pathways
• 11:56
  Speaker 1: for simplified and fast-track procedures.
• 12:00
  Speaker 2: Yes, those are very important distinctions.
• 12:02
  Speaker 1: But I have to ask, aren't fast-track and simplified just
• 12:05
  Speaker 1: bureaucratic synonyms? If I'm a pharmaceutical exec, can't I just
• 12:09
  Speaker 1: use these interchangeably to speed things up?
• 12:11
  Speaker 2: Treating those two pathways as interchangeable is a massive risk.
• 12:15
  Speaker 2: It's a critical error. The mechanisms and eligibility conditions behind
• 12:19
  Speaker 2: them are entirely distinct.
• 12:21
  Speaker 1: Okay, so what's the difference?
• 12:23
  Speaker 2: Well, a simplified procedure is applied based on low economic complexity.
• 12:28
  Speaker 2: This is typically for generics or drugs where the budget
• 12:30
  Speaker 2: impact is highly predictable and negligible.
• 12:33
  Speaker 1: So it's easy math for the agency.
• 12:35
  Speaker 2: Right. The assessment is faster because there isn't a complex
• 12:38
  Speaker 2: multivariable economic debate required. The fast-track procedure, though, is entirely different.
• 12:44
  Speaker 2: How so? It is based on severe, unmet medical need.
• 12:48
  Speaker 2: This is often for rare diseases or aggressive oncology indications,
• 12:51
  Speaker 2: where patients literally do not have time to wait for
• 12:54
  Speaker 2: a standard review cycle.
• 12:56
  Speaker 1: Ah, so a fast-track procedure could still be incredibly complex
• 12:59
  Speaker 1: scientifically and economically, but the agency is just prioritizing it
• 13:03
  Speaker 1: in the queue.
• 13:04
  Speaker 2: Yes, exactly. The complexity of the HTA evaluation doesn't diminish
• 13:08
  Speaker 2: in a fast-track. The agency simply dedicates concentrated resources to
• 13:12
  Speaker 2: assess it rapidly.
• 13:13
  Speaker 1: Okay, that makes sense.
• 13:15
  Speaker 2: If we use a hospital analogy, the fast-track pathway is
• 13:18
  Speaker 2: the emergency room triage. The patient has a severe, life-threatening condition,
• 13:22
  Speaker 2: so all specialists are pulled in immediately to address a
• 13:25
  Speaker 2: highly complex trauma.
• 13:27
  Speaker 1: And the simplified procedure.
• 13:28
  Speaker 2: The simplified procedure, on the other hand, is like the
• 13:31
  Speaker 2: pharmacy express checkout lane. You are buying something standard, the
• 13:34
  Speaker 2: price is known, and you just need to swipe your
• 13:37
  Speaker 2: card and leave.
• 13:37
  Speaker 1: Oh, wow. So if you try to take a complex,
• 13:39
  Speaker 1: novel biologic through the express checkout lane.
• 13:42
  Speaker 2: By applying for a simplified procedure, yes, your dossier will
• 13:45
  Speaker 2: be rejected because you were in the wrong structural pathway.
• 13:48
  Speaker 1: Given how easily a company can pick the wrong bureaucratic
• 13:51
  Speaker 1: lane and just ruin their timeline, there has to be
• 13:54
  Speaker 1: a systematic way to pressure test a launch strategy before
• 13:57
  Speaker 1: submitting anything.
• 13:58
  Speaker 2: And there is. That is really the core of the
• 14:00
  Speaker 2: DD-REG material.
• 14:02
  Speaker 1: Right. The seven-step regulatory-to-access roadmap designed specifically for this 2026 landscape.
• 14:09
  Speaker 1: We don't just want to read a list here, so
• 14:10
  Speaker 1: let's break this down into the friction points.
• 14:12
  Speaker 2: Good idea.
• 14:13
  Speaker 1: The first phase is essentially structural preparation. Step one is
• 14:17
  Speaker 1: defining your authorization route, and step two is assessing your
• 14:20
  Speaker 1: dossier readiness. They emphasize heavily reviewing the common technical document,
• 14:25
  Speaker 1: the CTD.
• 14:26
  Speaker 2: The CTD is vital. It is not just a filing
• 14:29
  Speaker 2: cabinet of paperwork. It is the foundational DNA of your
• 14:32
  Speaker 2: drug's clinical and chemical story.
• 14:34
  Speaker 1: Okay.
• 14:35
  Speaker 2: Step two of the roadmap focuses on early gap analysis
• 14:38
  Speaker 2: within that CTD. If you wait until you are formatting
• 14:41
  Speaker 2: your final e-dossier to realize your Phase 3 trials didn't
• 14:45
  Speaker 2: capture the specific quality of life metrics that AIFA demands
• 14:48
  Speaker 2: for reimbursement.
• 14:49
  Speaker 1: You're in trouble.
• 14:50
  Speaker 2: You are looking at a multi-million euro delay. You have
• 14:53
  Speaker 2: to ruthlessly audit your product information and clinical evidence against
• 14:57
  Speaker 2: AIFA's specific requirements long before submission. Which leads to Step 3,
• 15:03
  Speaker 2: identifying those specific AIFA requirements. And Step 4, building your
• 15:07
  Speaker 2: evidence strategy.
• 15:08
  Speaker 1: So what does this all mean in terms of internal
• 15:11
  Speaker 1: company dynamics? I look at step five of the roadmap,
• 15:14
  Speaker 1: coordinating regulatory and market access teams, and it reminds me
• 15:17
  Speaker 1: of producing a movie. A movie?
• 15:19
  Speaker 2: Yeah. Tell me more about that.
• 15:21
  Speaker 1: Well, if you're producing a massive project, the clinical scientists
• 15:24
  Speaker 1: are your script writers, right? Generating the data and the
• 15:26
  Speaker 1: story of how the drug works.
• 15:28
  Speaker 2: Okay. I see where you're going with this.
• 15:30
  Speaker 1: The regulatory affairs team is the director, making sure the
• 15:33
  Speaker 1: story meets all the compliance rules and gets a green
• 15:36
  Speaker 1: light from the studio. And the market access team are
• 15:39
  Speaker 1: the commercial marketers trying to sell the value of this
• 15:42
  Speaker 1: movie to a highly skeptical audience, in this case, AIFA.
• 15:45
  Speaker 2: That's spot on.
• 15:46
  Speaker 1: If these departments operate in silos, the launch will be
• 15:49
  Speaker 1: a disaster. The market access team might go to AIFA
• 15:52
  Speaker 1: promising a revolutionary cost-saving intervention. But if the clinical team
• 15:56
  Speaker 1: only designed trials to prove basic safety and non-inferiority, the
• 16:01
  Speaker 1: regulators are going to look at the data, see the disconnect,
• 16:04
  Speaker 1: and deny reimbursement.
• 16:06
  Speaker 2: The silo effect is the primary cause of delayed patient access.
• 16:09
  Speaker 2: When regulatory approval and market access are treated as a
• 16:13
  Speaker 2: single milestone, companies fail.
• 16:15
  Speaker 1: Because they think it's one smooth line. Right.
• 16:18
  Speaker 2: The regulatory team secures the EMA approval, throws it over
• 16:21
  Speaker 2: the wall to the market access team and says, we
• 16:23
  Speaker 2: got the authorization, now go negotiate the price.
• 16:26
  Speaker 1: And then what happens?
• 16:27
  Speaker 2: The market access team looks at the clinical evidence and
• 16:29
  Speaker 2: realizes that It entirely lacks the comparative health economic data
• 16:33
  Speaker 2: that IFA's 2026 guidelines legally require.
• 16:36
  Speaker 1: Oh, no.
• 16:36
  Speaker 2: To fix that, the company has to generate real-world evidence
• 16:40
  Speaker 2: or run new localized studies, which delays actual patient access
• 16:43
  Speaker 2: by months, if not years. Early gap analysis and cross-functional
• 16:48
  Speaker 2: coordination is the only way to survive.
• 16:50
  Speaker 1: Which feeds right into the final phases of the blueprint.
• 16:53
  Speaker 1: Step six is planning the post-authorization activities, and step seven
• 16:57
  Speaker 1: is continuously monitoring regulatory shifts.
• 17:00
  Speaker 2: Yes, planning for the regional implementation.
• 17:03
  Speaker 1: You have to map out exactly how you are going
• 17:05
  Speaker 1: to transition from that national IFA pricing agreement down into
• 17:09
  Speaker 1: the trenches of the regional formularies, all while keeping an
• 17:12
  Speaker 1: eye on how the EU joint clinical assessment regulations might
• 17:15
  Speaker 1: evolve next quarter.
• 17:16
  Speaker 2: The roadmap dictates a proactive, integrated orchestration of data. IFA
• 17:22
  Speaker 2: in 2026 expects total transparency, unquestionable comparative evidence, and a
• 17:27
  Speaker 2: perfectly aligned narrative. You have to prove that clinical superiority
• 17:31
  Speaker 2: translates directly into economic value for the Italian health care system.
• 17:35
  Speaker 1: And that brings us to the ultimate takeaway for you
• 17:37
  Speaker 1: listening to this deep dive. Navigating the Italian pharmaceutical market
• 17:41
  Speaker 1: requires a massive perspective shift.
• 17:44
  Speaker 2: It really does. It's a whole new world.
• 17:47
  Speaker 1: The journey does not begin when you submit your regulatory dossier,
• 17:50
  Speaker 1: and it certainly doesn't end when you get your EMA
• 17:53
  Speaker 1: approval letter. Succeeding in Italy means planning your clinical evidence
• 17:57
  Speaker 1: and economic strategy long before you ever seek your initial authorization.
• 18:01
  Speaker 2: Years in advance.
• 18:02
  Speaker 1: Exactly. You have to know exactly what economic and comparative
• 18:06
  Speaker 1: value AIFA will demand, select the right regulatory door, master
• 18:10
  Speaker 1: the new 2026E dossier requirements, and ensure your clinical, regulatory,
• 18:15
  Speaker 1: and commercial teams are all reading from the exact same
• 18:17
  Speaker 1: script from day one.
• 18:19
  Speaker 2: And as we close... The realities we've analyzed today leave
• 18:22
  Speaker 2: us with a significant strategic question to consider.
• 18:25
  Speaker 1: Let's hear it.
• 18:26
  Speaker 2: Well, given that Italy's regional health care arrangements and local
• 18:29
  Speaker 2: procurement boards ultimately dictate practical drug availability, even after AIFA
• 18:34
  Speaker 2: grants national pricing and reimbursement, how might pharmaceutical companies need
• 18:39
  Speaker 2: to completely redesign their local, region-by-region lobbying and educational tactics
• 18:44
  Speaker 2: within Italy's borders to ensure their treatments actually reach the
• 18:48
  Speaker 2: patients who need them?
• 18:49
  Speaker 1: It is a complex, high-stakes puzzle for any organization trying
• 18:53
  Speaker 1: to bridge the gap between regulatory success and true patient access.
• 18:57
  Speaker 1: Thank you for joining us on this deep dive into
• 18:59
  Speaker 1: the DD Reg Pharma market access landscape. Keep strategizing, keep
• 19:03
  Speaker 1: digging into the data, and we will catch you on
• 19:05
  Speaker 1: the next deep dive.